Tiziana Life Sciences (NASDAQ:TLSA) plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.
The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors. In parallel, Tiziana’s wholly owned biologic portfolio includes foralumab, a fully human anti‐CD3 monoclonal antibody investigated for autoimmune and neuroinflammatory conditions, and TZLS‐501, an anti‐interleukin‐6 receptor antibody initially evaluated for acute respiratory distress syndrome associated with infectious diseases.
Tiziana Life Sciences serves markets in North America and Europe, collaborating with academic centers and contract research organizations to conduct its clinical programs. The company’s multidisciplinary team combines expertise in translational research, medicinal chemistry and antibody engineering to support its pipeline from early discovery through clinical development.
Since joining Tiziana as chief executive officer in 2019, Dr. Bahija Jallal has leveraged her experience in biotechnology and immunotherapy to steer the company’s strategic direction. Supported by a board of directors and scientific advisory board with extensive pharmaceutical development backgrounds, Tiziana is advancing its programs toward regulatory milestones with the goal of addressing unmet needs in cancer and immune‐mediated diseases.
